Home › Funds › Sessa Capital IM, L.P. › SABS
Sessa Capital IM, L.P. position in SABS
SAB BIOTHERAPEUTICS INC · Health Care
Sessa Capital IM, L.P. reported holding 2,198,457 shares of SABS (SAB BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$8.6M, representing 0.14% of its reported portfolio and ranking #26 among its reported holdings. Sessa Capital IM, L.P. has disclosed SABS holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Sessa Capital IM, L.P.'s SABS position evolved
Sessa Capital IM, L.P. first disclosed a stake in SABS in Q4 2023 at 4,584,571 shares (US$3.2M). The position peaked in Q2 2026 at 2,198,457 shares, worth US$8.6M. Across 11 filings, Sessa Capital IM, L.P. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 8 time(s). The most recent filing (Q2 2026) shows 2,198,457 shares valued at US$8.6M. Notable position changes include a 90% trim in Q1 2024 (shares fell 32% over the following quarter), a 380% increase in Q3 2025 (shares rose 86% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 4.58M | $3.15M | New |
| Q1 2024 | 458.46K | $2.08M | Reduce |
| Q2 2024 | 458.46K | $1.42M | Hold |
| Q3 2024 | 458.46K | $1.24M | Hold |
| Q4 2024 | 458.46K | $1.74M | Hold |
| Q1 2025 | 458.46K | $623.50K | Hold |
| Q2 2025 | 458.46K | $804.59K | Hold |
| Q3 2025 | 2.20M | $4.42M | Add |
| Q4 2025 | 2.20M | $8.22M | Hold |
| Q1 2026 | 2.20M | $8.42M | Hold |
| Q2 2026 | 2.20M | $8.57M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SABS and 13F data
SABS (SAB BIOTHERAPEUTICS INC) is a Health Care company. 77 other funds we track also report a position in SABS — the largest reported positions include Caligan Partners LP (US$31.1M), Vivo Capital, LLC (US$28.5M), Commodore Capital LP (US$11.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SABS
- Caligan Partners LP 7.97M sh · $31.07M · Q2 2026
- Vivo Capital, LLC 7.30M sh · $28.47M · Q2 2026
- Commodore Capital LP 2.87M sh · $11.19M · Q2 2026
- Spruce Street Capital LP 2.20M sh · $8.57M · Q2 2026
- Propel Bio Management, LLC 1.08M sh · $4.20M · Q2 2026
- Seven Fleet Capital Management LP 736.08K sh · $2.87M · Q2 2026
More on Sessa Capital IM, L.P.
FAQ
How long has Sessa Capital IM, L.P. held SABS?
Sessa Capital IM, L.P. has disclosed SABS holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is Sessa Capital IM, L.P.'s current position in SABS?
As of Q2 2026, Sessa Capital IM, L.P. holds 2.20M shares of SABS (SAB BIOTHERAPEUTICS INC), valued at $8.57M, representing 0.14% of its reported portfolio and ranking #26.
Has Sessa Capital IM, L.P. been buying or selling SABS?
In the latest 13F filing (Q2 2026), Sessa Capital IM, L.P. held unchanged its position in SABS. The position peaked in Q2 2026 at 2.20M shares.
Which other funds hold SABS?
Other major institutional holders of SABS include Caligan Partners LP, Vivo Capital, LLC, Commodore Capital LP, among 77 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.